|   
 | 
| 
|  |  | HR0703 |  | LRB093 19758 KEF 47577 r |  | 
| 
 
 | 
| 1 |  | HOUSE RESOLUTION
 
 | 
| 2 |  |     WHEREAS, Hemophilia is a genetic condition affecting  | 
| 3 |  | approximately 700 persons in the State of Illinois; hemophilia  | 
| 4 |  | is characterized by the absence of one of the several clotting  | 
| 5 |  | factors necessary to control bleeding; the standard care for  | 
| 6 |  | the treatment of hemophilia is to replace the absent clotting  | 
| 7 |  | factors necessary to control bleeding; and
 | 
| 8 |  |     WHEREAS, Without treatment, people with hemophilia face  | 
| 9 |  | frequent, spontaneous bleeding episodes in their joints  | 
| 10 |  | causing swelling in the joint, muscles, internal organs, and  | 
| 11 |  | brain; repeated bleeding episodes in joints result in a chronic  | 
| 12 |  | degenerative arthritic condition, which often leads to  | 
| 13 |  | frequent hospitalizations, permanent disability, and chronic  | 
| 14 |  | pain; bleeding episodes involving internal organs and the brain  | 
| 15 |  | can cause permanent damage, disability, and even death; and
 | 
| 16 |  |     WHEREAS, Severe bleeding episodes result in lost time at  | 
| 17 |  | work and school, decreased quality of life, and inability to  | 
| 18 |  | perform basic living activities; and
 | 
| 19 |  |     WHEREAS, With proper care and access to comprehensive  | 
| 20 |  | medical resources, persons with hemophilia can control  | 
| 21 |  | bleeding episodes and can lead productive lives; and
 | 
| 22 |  |     WHEREAS, The Medical and Scientific Advisory Committee of  | 
| 23 |  | the National Hemophilia Foundation recommends recombinant  | 
| 24 |  | factor products as the treatment of choice for persons with  | 
| 25 |  | hemophilia VIII and IX; and
 | 
| 26 |  |     WHEREAS, Visits to Hemophilia Treatment Centers reduced  | 
| 27 |  | morbidity by 60 percent; and
 | 
| 28 |  |     WHEREAS, The State of Illinois is committed to the proper  | 
| 29 |  | medical treatment of hemophilia; and
 |